Literature DB >> 20824009

uPAR and HER2 Genes Are Usually Co-Amplified in Individual Breast Cancer Cells from Blood and Tissues.

Jonathan Uhr1.   

Abstract

Entities:  

Year:  2008        PMID： 20824009      PMCID： PMC2930997          DOI： 10.1159/000151738

Source DB:  PubMed          Journal:  Breast Care (Basel)        ISSN： 1661-3791            Impact factor:   2.860


× No keyword cloud information.
  21 in total

1.  Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer.

Authors:  Martine J Piccart-Gebhart; Marion Procter; Brian Leyland-Jones; Aron Goldhirsch; Michael Untch; Ian Smith; Luca Gianni; Jose Baselga; Richard Bell; Christian Jackisch; David Cameron; Mitch Dowsett; Carlos H Barrios; Günther Steger; Chiun-Shen Huang; Michael Andersson; Moshe Inbar; Mikhail Lichinitser; István Láng; Ulrike Nitz; Hiroji Iwata; Christoph Thomssen; Caroline Lohrisch; Thomas M Suter; Josef Rüschoff; Tamás Suto; Victoria Greatorex; Carol Ward; Carolyn Straehle; Eleanor McFadden; M Stella Dolci; Richard D Gelber
Journal:  N Engl J Med       Date:  2005-10-20       Impact factor: 91.245

2.  Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer.

Authors:  Edward H Romond; Edith A Perez; John Bryant; Vera J Suman; Charles E Geyer; Nancy E Davidson; Elizabeth Tan-Chiu; Silvana Martino; Soonmyung Paik; Peter A Kaufman; Sandra M Swain; Thomas M Pisansky; Louis Fehrenbacher; Leila A Kutteh; Victor G Vogel; Daniel W Visscher; Greg Yothers; Robert B Jenkins; Ann M Brown; Shaker R Dakhil; Eleftherios P Mamounas; Wilma L Lingle; Pamela M Klein; James N Ingle; Norman Wolmark
Journal:  N Engl J Med       Date:  2005-10-20       Impact factor: 91.245

3.  uPAR and HER-2 gene status in individual breast cancer cells from blood and tissues.

Authors:  Songdong Meng; Debu Tripathy; Sanjay Shete; Raheela Ashfaq; Hossein Saboorian; Barbara Haley; Eugene Frenkel; David Euhus; Marilyn Leitch; Cynthia Osborne; Edward Clifford; Steve Perkins; Peter Beitsch; Amanullah Khan; Larry Morrison; Dorothee Herlyn; Leon W M M Terstappen; Nancy Lane; Jianqiang Wang; Jonathan Uhr
Journal:  Proc Natl Acad Sci U S A       Date:  2006-11-01       Impact factor: 11.205

4.  Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene.

Authors:  D J Slamon; G M Clark; S G Wong; W J Levin; A Ullrich; W L McGuire
Journal:  Science       Date:  1987-01-09       Impact factor: 47.728

Review 5.  The urokinase receptor as a potential target in cancer therapy.

Authors:  John Romer; Boye Schnack Nielsen; Michael Ploug
Journal:  Curr Pharm Des       Date:  2004       Impact factor: 3.116

6.  Patterns of aneusomy for three chromosomes in individual cells from breast cancer tumors.

Authors:  Tanja Fehm; Larry Morrison; H Saboorian; Linda Hynan; Thomas Tucker; Jonathan Uhr
Journal:  Breast Cancer Res Treat       Date:  2002-10       Impact factor: 4.872

7.  Comparative evaluation of urokinase-type plasminogen activator receptor expression in primary breast carcinomas and on metastatic tumor cells.

Authors:  Alice Hemsen; Lutz Riethdorf; Nils Brünner; Jürgen Berger; Sebastian Ebel; Christoph Thomssen; Fritz Jänicke; Klaus Pantel
Journal:  Int J Cancer       Date:  2003-12-20       Impact factor: 7.396

8.  Cytogenetic evidence that circulating epithelial cells in patients with carcinoma are malignant.

Authors:  Tanja Fehm; Arthur Sagalowsky; Edward Clifford; Peter Beitsch; Hossein Saboorian; David Euhus; Songdong Meng; Larry Morrison; Thomas Tucker; Nancy Lane; B Michael Ghadimi; Kerstin Heselmeyer-Haddad; Thomas Ried; Chandra Rao; Jonathan Uhr
Journal:  Clin Cancer Res       Date:  2002-07       Impact factor: 12.531

Review 9.  Anti-erbB-2 antibody trastuzumab in the treatment of HER2-amplified breast cancer.

Authors:  Christina H Yeon; Mark D Pegram
Journal:  Invest New Drugs       Date:  2005-10       Impact factor: 3.651

10.  Prognostic impact of urokinase-type plasminogen activator receptor (uPAR) in cytosols and pellet extracts derived from primary breast tumours.

Authors:  J H de Witte; J A Foekens; N Brünner; J J Heuvel; T van Tienoven; M P Look; J G Klijn; A Geurts-Moespot; N Grebenchtchikov; T Benraad; C G Sweep
Journal:  Br J Cancer       Date:  2001-07-06       Impact factor: 7.640
View more
  2 in total

Review 1.  HER2 and uPAR cooperativity contribute to metastatic phenotype of HER2-positive breast cancer.

Authors:  Vineesh Indira Chandran; Serenella Eppenberger-Castori; Thejaswini Venkatesh; Kara Lea Vine; Marie Ranson
Journal:  Oncoscience       Date:  2015-03-23

Review 2.  Urokinase receptor and resistance to targeted anticancer agents.

Authors:  Steven L Gonias; Jingjing Hu
Journal:  Front Pharmacol       Date:  2015-07-27       Impact factor: 5.810
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.